Prediction of Medication Compliance Following Renal Transplantation
2 other identifiers
observational
30
1 country
1
Brief Summary
The purpose of this study is to quantitate pre-transplant medication compliance, dialysis compliance, and related psychological variables, and then examine their validity as predictors of post-transplant noncompliant behaviors and clinically relevant outcomes (acute rejection, graft loss, or death). Hypothesis: Noncompliance with pre-transplant medication or with the dialysis prescription, and specific psychological variables predict similarly noncompliant behaviors after transplantation.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started Jan 2003
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2003
CompletedFirst Submitted
Initial submission to the registry
September 2, 2005
CompletedFirst Posted
Study publicly available on registry
September 7, 2005
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 1, 2014
CompletedStudy Completion
Last participant's last visit for all outcomes
November 1, 2014
CompletedJune 1, 2015
May 1, 2015
11.8 years
September 2, 2005
May 28, 2015
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Prediction of early medication adherence
Prediction of declining medication adherence during first three months post kidney transplantation.
3 months
Eligibility Criteria
Pre-operative renal transplant recipients
You may qualify if:
- Adult hemodialysis patients in renal transplant evaluation
- Able to read test forms
- Responsible for their own medications
You may not qualify if:
- Patients with a major risk of recurrent primary renal disease, e.g. hemolytic uremic syndrome, oxalosis, membranoproliferative glomerulonephritis type II, focal segmental glomerulosclerosis with nephrotic syndrome.
- Patients with active psychosis
- Patients who do not speak English.
- Patients who live and will be followed outside the United States, except Canada.
- Patients who are physically unable to open the Medication Event Monitoring System (MEMS) cap.
- Patients who are not responsible for taking their own medications, e.g. living in a medical care facility.
- Patients who are younger than 14 years old
- Patients who will receive an extra renal organ (except pancreas), either simultaneously or previously.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
University of Minnesota
Minneapolis, Minnesota, 55455, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Thomas E Nevins, MD
University of Minnesota
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
September 2, 2005
First Posted
September 7, 2005
Study Start
January 1, 2003
Primary Completion
November 1, 2014
Study Completion
November 1, 2014
Last Updated
June 1, 2015
Record last verified: 2015-05